• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Why I Now Use Belotero for All My Dermal Filler Treatments — A Personal Clinical Review

I have been performing dermal filler treatments for over twenty years.

In that time I have used most of the leading hyaluronic acid fillers on the market. I have watched the field progressively evolve, and have developed strong views about which products I trust, based on clinical experience rather than brand loyalty. Read more about

Why I will only use Belotero hyaluronic fillers from
Merz Aesthetics

By Dr Peter Forrester
The Doctors Company, Esher Surrey

Eight years ago I first started using Belotero hyaluronic acid dermal fillers, made by Merz Aesthetics. I have not used another hyaluronic acid filler since then.

The reason is straightforward: in eight years and several treatments, I have not seen a single inflammatory reaction.

That may not sound remarkable until you how common — and how accepted inflammatory reactions are with other fillers. This post explains my clinical journey, what eventually prompted me to change, and what the scientific evidence tells us about why Belotero behaves .

The Early Years of Hyaluronic Acid Fillers

Restylane was the world's first non-animal hyaluronic acid filler, launched in Europe in 1996. It represented a ground breaking advance — replacing earlier animal-derived products that carried significant risks, and offering results that were more and longer lasting than the collagen-based fillers that preceded them.

I began using Restylane in 2003. In a busy practice, inflammatory reactions were an occasional but fully expected part of the clinical picture. Once or sometimes twice a year, a would develop a reaction — ranging from a small palpable nodule beneath the skin to a more generalised inflammatory requiring oral steroids or hyaluronidase injections to dissolve the filler. These reactions could occur weeks or even months after treatment.

These reactions were not a failing. They were considered a known risk and patients were routinely about them as part of the consent .

Over the following years I tried other hyaluronic acid fillers as they came to market. The experience was broadly similar. The products differed in consistency, longevity and handling characteristics, but the occasional inflammatory reaction remained a constant. It was simply part of the landscape.

My views on hyaluronic dermal are based on 20 years of clinical experience and the critical approach that comes from a science-based medical education and training.

A Prompt to Change

About eight years ago, I noticed an increase in the frequency of reactions with a filler I was using at the time — Juvéderm, a widely-used and popular filler. It was enough to prompt me to reconsider my product choice, and I switched to the Belotero range of Hyaluronic Acid (HA) filers.

Because reactions had been so infrequent with products — once or twice a year at most — it took me approximately three years to consciously register that I hadn't seen one since switching to . There was no dramatic moment of realisation. The absence was so gradual that I simply hadn't noticed it.

But once I did notice, I began to pay close attention. Another year passed. Then . Now, eight years and several thousand syringes later, I have still not seen one single inflammatory reaction with Belotero.

Not one nodule. Not one generalised reaction. Not one patient requiring hyaluronidase or for a delayed inflammatory response

Why Does This Matter?

It is not a clinical trial. It is the experience of one practitioner, in one practice, over eight years. There are limits to what can be concluded from that alone.

But it is also not nothing. Twenty years of comparative experience with multiple products, followed by eight consecutive years without a single reaction with one product, is clinically meaningful. It is the kind of pattern that demands explanation — and, I believe, a change in practice.

My view is that many practitioners simply continue using other fillers because reactions remain relatively infrequent and are so thoroughly normalised that their absence is never noticed. You do not miss what you have come to expect.

None of this is to suggest that other hyaluronic acid fillers are unsafe. They are not. Inflammatory reactions with all HA fillers remain relatively uncommon, and many excellent practitioners use other products to very good effect.

Equally, the vascular complications that represent the most risks of any filler — which are related to injection technique and anatomy rather than the product itself — require the same vigilance regardless of which filler is used. Product choice does not replace clinical skill and knowledge.

What I am saying is this: in my clinical over twenty years, and by the scientific evidence now emerging about particulate impurities and tissue integration, Belotero behaves differently from other fillers in one specific and important respect. It does not cause inflammatory reactions in my hands.

That is a significant clinical advantage — and one that I think is underappreciated in the broader aesthetic community, precisely because reactions with other fillers are so normalised that their absence goes .

What the Science Tells Us

Unlike most other hyaluronic acid fillers, which are cross-linked once during manufacture, Belotero is produced using a process called Cohesive Polydensified Matrix (CPM) technology, Anti-Wrinkle Subscription in which the hyaluronic acid undergoes continuous cross-linking. This creates a gel with variable density — areas of higher and lower cross-linking within the same product — that gives it unique physical properties.

The practical result is that Belotero integrates into tissue in a more homogeneous and natural way than other fillers. Histological studies comparing Belotero directly with Juvéderm and Restylane have shown that it distributes more evenly within the collagen and elastin architecture of the dermis, filling even the smallest spaces between fibres without disrupting the structural integrity of the surrounding tissue. Rather than sitting as a discrete bolus, it becomes part of the tissue.

This matters clinically because the more foreign and physically disruptive a material is to the surrounding tissue, the more likely it is to provoke an immune response.

Emerging research has identified another important factor: particulate impurities in hyaluronic acid fillers.

A 2026 peer-reviewed study examined the particulate of CPM hyaluronic acid fillers and their inflammatory potential. The findings were striking. CPM fillers showed very low levels of — well beneath pharmacopeial thresholds for injectables — and importantly, analysis confirmed the absence of immunologically relevant materials such as silicon, iron and aluminium, which have been identified in other HA filler products and are known to act as immune adjuvants, priming the tissue for inflammatory reactions.

In vivo biopsy analysis at one and four weeks after injection showed no inflammatory or granulomatous response in human skin.

The study concluded that CPM fillers demonstrate high purity with minimal particulate matter and no potential immunologic adjuvants, with in vivo analyses confirming an absence of inflammatory responses.

The broader clinical literature supports this picture. A comprehensive review of 26 published studies covering the Belotero range found no reports of the effect, nodules, granulomas or tissue necrosis across the entire family. The most common adverse effects were mild, temporary redness, swelling and bruising — in other words, the normal consequences of any injection.

A five-year retrospective safety review of 317 patients repeatedly with Belotero found no severe adverse events in any patient. A long-term clinical trial following patients for up to 96 weeks found that of 34 total adverse events recorded, only one — injection-site bruising — was considered related to the product itself.

The published conclusion is consistent: the Belotero range demonstrates sustainable aesthetic effects, a good safety profile, and long-term tolerability. Read here about

Conclusion

Choosing a dermal filler is not simply a matter of choosing a brand. The physical and chemical properties of a product — how it is manufactured, how it integrates into tissue, how pure it is — have real consequences for patients.

My switch to Belotero eight years ago was prompted by a clinical concern. What I have observed since has exceeded any expectation I had at the time. The science, I believe, explains why.

If you are considering , the choice of product matters — but it matters less than the experience and judgement of the person using it. At the Cosmetic Doctors Company, all treatments are performed by our medically qualified doctors, with products chosen on the basis of clinical evidence and long-term patient safety.

To Book a Consultation :

If you would like to explore any of our curated range of services, we would be pleased to arrange a consultation. At the Cosmetic Doctors Company your consultation and any subsequent treatment will always be with one of our expert, medically qualified doctors.

To make a booking with one of our doctors please use the links below to telephone or email or .

The Frozen Face in Aesthetic Medicine — Separating Fact from Fiction

Biostimulation in Aesthetic Medicine — The Future of Natural Skin Rejuvenation

6 Esher Park Avenue
Esher, Surrey KT10 9NP

Tel: ‬
Tel: ‭ ‬

© 2026
The Cosmetic Ltd
Company no.